InvestorsHub Logo
Followers 3
Posts 114
Boards Moderated 0
Alias Born 10/02/2017

Re: None

Wednesday, 06/19/2019 12:51:57 PM

Wednesday, June 19, 2019 12:51:57 PM

Post# of 2001
Global Cutaneous T-Cell Lymphoma (CTCL) Market Spotlight

“High-impact upcoming events for drugs in the CTCL space comprise topline Phase III trial results for SGX301, and topline Phase II trial results for resminostat.”

https://www.businesswire.com/news/home/20190619005312/en/Global-Cutaneous-T-Cell-Lymphoma-CTCL-Market-Spotlight

In my opinion Medivir will need to pay Tetralogic soon. They better start looking for options.